{"id":"spd489","rwe":[{"pmid":"40975435","year":"2025","title":"Moderators of Response to Stimulants for Preschool Attention-Deficit/Hyperactivity Disorder.","finding":"","journal":"Journal of the American Academy of Child and Adolescent Psychiatry","studyType":"Clinical Study"},{"pmid":"29383572","year":"2018","title":"Cognitive Function of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder in a 2-Year Open-Label Study of Lisdexamfetamine Dimesylate.","finding":"","journal":"CNS drugs","studyType":"Clinical Study"},{"pmid":"29258368","year":"2018","title":"Lisdexamfetamine: chemistry, pharmacodynamics, pharmacokinetics, and clinical efficacy, safety, and tolerability in the treatment of binge eating disorder.","finding":"","journal":"Expert opinion on drug metabolism & toxicology","studyType":"Clinical Study"},{"pmid":"26714249","year":"2015","title":"[Lisdexamfetamine dimesylate: a Treatment Option for Children and Adolescents with Attention Deficit/Hyperactivity Disorder in Germany and Across Europe].","finding":"","journal":"Fortschritte der Neurologie-Psychiatrie","studyType":"Clinical Study"},{"pmid":"25526678","year":"2015","title":"Interpreting the results of a retrospective comparison of test and reference treatments in a randomized clinical trial setting.","finding":"","journal":"Clinical drug investigation","studyType":"Clinical Study"}],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"},{"label":"Shire","category":"company"}],"phase":"marketed","safety":{},"trials":[],"aliases":["lisdexamfetamine dimesylate, LDX, Vyvanse","Lisdexmfetamine dimesylate","Vyvanse","Lisdexamfetamine dimesylate","Vyvanse, Lisdexamfetamine dimesylate, LDX"],"company":"Shire","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=SPD489","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:28:53.710055+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:28:58.621831+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=SPD489","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:28:59.053924+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201222/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:28:59.764634+00:00"}},"allNames":["spd489"],"offLabel":[],"synonyms":[],"timeline":[],"approvals":[],"ecosystem":[],"mechanism":{"modality":"Small Molecule","explanation":"","oneSentence":"","technicalDetail":"spd489 is a small molecule that binds to a specific protein or receptor, altering its activity and leading to a therapeutic effect."},"commercial":{},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=spd489","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=spd489","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-31T10:24:57.342396","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:29:01.546361+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[],"genericName":"spd489","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT01718509","phase":"PHASE3","title":"SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder","status":"COMPLETED","sponsor":"Shire","startDate":"2012-11-26","conditions":["Binge Eating Disorder"],"enrollment":390,"completionDate":"2013-09-20"},{"nctId":"NCT01760993","phase":"PHASE3","title":"Long-term Safety of SPD489 When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia","status":"TERMINATED","sponsor":"Shire","startDate":"2013-02-01","conditions":["Schizophrenia"],"enrollment":2,"completionDate":"2013-04-01"},{"nctId":"NCT01738698","phase":"PHASE3","title":"Adjunctive SPD489 to Antipsychotic Medication in Clinically Stable Adults With Persistent Predominant Negative Symptoms of Schizophrenia","status":"TERMINATED","sponsor":"Shire","startDate":"2012-11-01","conditions":["Schizophrenia"],"enrollment":4,"completionDate":"2013-04-01"},{"nctId":"NCT01760889","phase":"PHASE3","title":"SPD489 Low Dose and High Dose Ranges When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia","status":"TERMINATED","sponsor":"Shire","startDate":"2013-02-01","conditions":["Schizophrenia"],"enrollment":1,"completionDate":"2013-04-01"},{"nctId":"NCT00877487","phase":"PHASE4","title":"Safety and Efficacy of Vyvanse in Adults With Attention-Deficit/Hyperactivity Disorder","status":"COMPLETED","sponsor":"Shire","startDate":"2009-04-30","conditions":["Attention-Deficit/Hyperactivity Disorder"],"enrollment":123,"completionDate":"2010-07-08"},{"nctId":"NCT01235338","phase":"PHASE1","title":"Co-Administration of LDX (SPD489) and Venlafaxine XR (EFFEXOR XR) in Healthy Volunteers","status":"COMPLETED","sponsor":"Shire","startDate":"2010-10-28","conditions":["Healthy"],"enrollment":80,"completionDate":"2011-01-17"},{"nctId":"NCT01436175","phase":"PHASE3","title":"SPD489 Adult Major Depressive Disorder (MDD) Open-label Safety and Tolerability Rollover Extension Study","status":"TERMINATED","sponsor":"Shire","startDate":"2012-02-27","conditions":["Major Depressive Disorder"],"enrollment":1570,"completionDate":"2014-03-27"},{"nctId":"NCT01096680","phase":"PHASE2","title":"Pharmacodynamic Profile of SPD489 in Healthy Adult Males Undergoing a Nocturnal Period of Acute Sleep Loss","status":"COMPLETED","sponsor":"Shire","startDate":"2010-04-05","conditions":["Sleep Deprivation"],"enrollment":135,"completionDate":"2010-07-18"},{"nctId":"NCT02009163","phase":"PHASE3","title":"Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder","status":"COMPLETED","sponsor":"Shire","startDate":"2014-01-27","conditions":["Binge Eating Disorder"],"enrollment":418,"completionDate":"2015-04-08"},{"nctId":"NCT00905424","phase":"PHASE2","title":"Exploratory Study of SPD489 in Adults With Major Depressive Disorder (MDD) as Augmentation Therapy to an Antidepressant","status":"COMPLETED","sponsor":"Shire","startDate":"2009-07-30","conditions":["Major Depressive Disorder"],"enrollment":246,"completionDate":"2010-08-04"},{"nctId":"NCT01552902","phase":"PHASE4","title":"Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder","status":"COMPLETED","sponsor":"Shire","startDate":"2012-04-03","conditions":["Attention-deficit/Hyperactivity Disorder"],"enrollment":549,"completionDate":"2014-05-22"},{"nctId":"NCT01328756","phase":"PHASE4","title":"Lisdexamfetamine Dimesylate 2-year Safety Study in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)","status":"COMPLETED","sponsor":"Shire","startDate":"2011-07-07","conditions":["Attention Deficit Hyperactivity Disorder (ADHD)"],"enrollment":314,"completionDate":"2014-09-30"},{"nctId":"NCT01291173","phase":"PHASE2","title":"Forced-dose Titration of SPD489 in Adults With Binge Eating Disorder","status":"COMPLETED","sponsor":"Shire","startDate":"2011-05-10","conditions":["Binge Eating Disorder"],"enrollment":271,"completionDate":"2012-01-30"},{"nctId":"NCT00697515","phase":"PHASE3","title":"Safety and Efficacy Workplace Environment Study of Lisdexamfetamine Dimesylate (LDX) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)","status":"COMPLETED","sponsor":"Shire","startDate":"2008-07-18","conditions":["ADHD"],"enrollment":142,"completionDate":"2008-12-20"},{"nctId":"NCT01435759","phase":"PHASE2","title":"SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder","status":"COMPLETED","sponsor":"Shire","startDate":"2011-05-31","conditions":["Major Depressive Disorder"],"enrollment":1197,"completionDate":"2014-01-17"},{"nctId":"NCT01436162","phase":"PHASE3","title":"Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder","status":"COMPLETED","sponsor":"Shire","startDate":"2011-10-19","conditions":["Major Depressive Disorder"],"enrollment":1105,"completionDate":"2013-12-10"},{"nctId":"NCT00922272","phase":"PHASE2","title":"Efficacy, Safety, and Tolerability of SPD489 in Adults With Schizophrenia and Predominant Negative Symptoms","status":"COMPLETED","sponsor":"Shire","startDate":"2009-09-14","conditions":["Schizophrenia and Predominant Negative Symptoms"],"enrollment":92,"completionDate":"2011-01-20"},{"nctId":"NCT01436149","phase":"PHASE3","title":"Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder","status":"COMPLETED","sponsor":"Shire","startDate":"2011-10-27","conditions":["Major Depressive Disorder"],"enrollment":1262,"completionDate":"2013-12-23"},{"nctId":"NCT01657019","phase":"PHASE3","title":"Open Label Extension in Adults With Binge Eating Disorder (BED)","status":"COMPLETED","sponsor":"Shire","startDate":"2012-08-21","conditions":["Binge Eating Disorder"],"enrollment":604,"completionDate":"2014-10-21"},{"nctId":"NCT01101022","phase":"PHASE4","title":"Safety and Efficacy of SPD489 on Executive Function Behaviors in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)","status":"COMPLETED","sponsor":"Shire","startDate":"2010-05-19","conditions":["ADHD Specifically With Executive Function Impairment"],"enrollment":161,"completionDate":"2010-11-29"},{"nctId":"NCT00784654","phase":"PHASE3","title":"Double-blind, Placebo-controlled, Randomised Withdrawal, Extension, Safety and Efficacy Study of LDX in Children and Adolescents Aged 6-17","status":"COMPLETED","sponsor":"Shire","startDate":"2009-01-27","conditions":["ADHD"],"enrollment":276,"completionDate":"2011-10-26"},{"nctId":"NCT00985725","phase":"PHASE2","title":"SPD489 in Adults With Persistent Executive Function Impairments (EFI) and Partial or Full Remission of Recurrent Major Depressive Disorder","status":"COMPLETED","sponsor":"Shire","startDate":"2009-10-29","conditions":["Major Depressive Disorder"],"enrollment":143,"completionDate":"2011-04-18"},{"nctId":"NCT01552915","phase":"PHASE4","title":"Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder","status":"COMPLETED","sponsor":"Shire","startDate":"2012-04-17","conditions":["Attention-deficit/Hyperactivity Disorder"],"enrollment":464,"completionDate":"2014-01-22"},{"nctId":"NCT03260205","phase":"PHASE3","title":"Safety and Efficacy Study in Preschool Children Aged 4-5 Years With Attention-deficit/Hyperactivity Disorder (ADHD)","status":"COMPLETED","sponsor":"Shire","startDate":"2017-09-06","conditions":["Attention Deficit Hyperactivity Disorder (ADHD)"],"enrollment":199,"completionDate":"2018-10-23"},{"nctId":"NCT02402166","phase":"PHASE2","title":"Safety, Tolerability, Pharmacokinetic, and Efficacy Study of SPD489 in Preschool Children With Attention-deficit/Hyperactivity Disorder","status":"COMPLETED","sponsor":"Shire","startDate":"2015-04-15","conditions":["Attention Deficit Hyperactivity Disorder (ADHD)"],"enrollment":24,"completionDate":"2016-06-30"},{"nctId":"NCT01718483","phase":"PHASE3","title":"SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder","status":"COMPLETED","sponsor":"Shire","startDate":"2012-11-26","conditions":["Binge Eating Disorder"],"enrollment":383,"completionDate":"2013-09-25"},{"nctId":"NCT01234298","phase":"PHASE3","title":"SPD489 as Adjunctive Treatment in Adults With Negative Symptoms of Schizophrenia","status":"WITHDRAWN","sponsor":"Shire","startDate":"2012-01-27","conditions":["Negative Symptoms of Schizophrenia"],"enrollment":0,"completionDate":"2014-02-24"},{"nctId":"NCT01890785","phase":"PHASE1","title":"Bioavailability Study of SPD489 Administered With Two Different Means of Administration in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Shire","startDate":"2013-07-15","conditions":["Healthy Volunteers"],"enrollment":30,"completionDate":"2013-08-22"},{"nctId":"NCT01274221","phase":"PHASE3","title":"Safety and Efficacy of SPD489 in Adolescent Subjects Aged 13-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)","status":"WITHDRAWN","sponsor":"Shire","startDate":"2011-03-06","conditions":["ADHD"],"enrollment":0,"completionDate":"2011-05-04"},{"nctId":"NCT01457339","phase":"PHASE1","title":"Assess the Safety and Pharmacokinetics of Ascending, Multiple Oral Doses of SPD489 in Adults With Schizophrenia","status":"COMPLETED","sponsor":"Shire","startDate":"2011-10-21","conditions":["Schizophrenia"],"enrollment":31,"completionDate":"2012-01-20"},{"nctId":"NCT02466386","phase":"PHASE3","title":"Safety and Tolerability Study of SPD489 in Preschool Children Aged 4-5 Years, Diagnosed With Attention-deficit/Hyperactivity Disorder","status":"COMPLETED","sponsor":"Shire","startDate":"2015-08-21","conditions":["Attention Deficit Hyperactivity Disorder (ADHD)"],"enrollment":113,"completionDate":"2020-01-03"},{"nctId":"NCT00736255","phase":"NA","title":"Attention Deficit Hyperactivity Disorder (ADHD) Smoking Cessation Study","status":"COMPLETED","sponsor":"Duke University","startDate":"2007-12","conditions":["Attention Deficit Hyperactivity Disorder","Nicotine Dependence"],"enrollment":32,"completionDate":"2011-07"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"chemblId":"CHEMBL1201222"},"formularyStatus":[],"_enricherVersion":"v2-openfda","developmentCodes":[],"ownershipHistory":[{"period":"","companyName":"Shire","relationship":"Original Developer"}],"publicationCount":10,"therapeuticAreas":["Other"],"biosimilarFilings":[],"originalDeveloper":"Shire","recentPublications":[{"date":"2025 Sep 18","pmid":"40975435","title":"Moderators of Response to Stimulants for Preschool Attention-Deficit/Hyperactivity Disorder.","journal":"Journal of the American Academy of Child and Adolescent Psychiatry"},{"date":"2018 Jan","pmid":"29383572","title":"Cognitive Function of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder in a 2-Year Open-Label Study of Lisdexamfetamine Dimesylate.","journal":"CNS drugs"},{"date":"2018 Feb","pmid":"29258368","title":"Lisdexamfetamine: chemistry, pharmacodynamics, pharmacokinetics, and clinical efficacy, safety, and tolerability in the treatment of binge eating disorder.","journal":"Expert opinion on drug metabolism & toxicology"},{"date":"2015 Dec","pmid":"26714249","title":"[Lisdexamfetamine dimesylate: a Treatment Option for Children and Adolescents with Attention Deficit/Hyperactivity Disorder in Germany and Across Europe].","journal":"Fortschritte der Neurologie-Psychiatrie"},{"date":"2015 Feb","pmid":"25526678","title":"Interpreting the results of a retrospective comparison of test and reference treatments in a randomized clinical trial setting.","journal":"Clinical drug investigation"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","brandName":"SPD489","companyName":"Shire","companyId":"shire","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":6,"withResults":5},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:29:01.546361+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}